Chronic Refractory Cough Market – Market Insight, Epidemiology and Market Forecast – 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Chronic Refractory Cough – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This ‘Chronic Refractory Cough (CRC) – Market Insights, Epidemiology and Market Forecast- 2030’ report delivers an in-depth understanding of the Chronic Refractory Cough (CRC), historical and forecasted epidemiology as well as the Chronic Refractory Cough (CRC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Findings
This section includes a glimpse of the Chronic Refractory Cough (CRC) 7MM market.
- The market size of CRC in the seven major markets was estimated to be USD 6,118.6 Million in 2020, which is expected to show a positive growth at a CAGR of 6.57% during the study period 2018-2030.
- The United States accounts for the largest market size of CRC throughout the study period of 2018-2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 3,326.6 Million in 2020.
- Among the EU5 countries, France had the highest market size with USD 623.4 Million in 2020, while Spain had the lowest market size with USD 332.2 Million in 2020.
- The Japan CRC market accounted for USD 331.6 Million in 2020.
The Chronic Refractory Cough (CRC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic Refractory Cough (CRC) market size from 2018 to 2030. The report also covers current Chronic Refractory Cough (CRC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Report Highlights
- In the coming years, Chronic Refractory Cough (CRC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Refractory Cough (CRC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- The publisher has analysed the prevalent population of Chronic cough and CRC in the 7MM for the study period of 2018-2030.
- Diagnosed prevalence of CRC was also assessed, which suggests that the cases of CRC will increase during the forecast period of 2021-2030.
- In addition, the gender-specific prevalence of Chronic Cough was assessed as well. As per the analysis, CRC is more prevalent in females than in males.
- The scope of the report also encompasses another major segment, i.e., Diagnosed Prevalent Population of CRC in IPF patients, wherein the number of IPF patients suffering from CRC was calculated.
- Currently, the treatment regimen of CRC involves the use of Neuro-modulating agents (Opioids, Baclofen, Gabapentin, Pregablin, and Amitriptyline), Proton Pump inhibitors, Inhaled corticosteroids (ICs) and others.
- Expected Launch of potential therapies, Orvepitant Maleate, BLU-5937, Gefapixant (MK-7264), BAY1817080 (Eliapixant) and S-600918, may increase market size in the coming years, assisted by an increase in CRC prevalent population pool. Owing to the positive outcomes of the upcoming products by key players such as Nerre Therapeutics, Bellus Health, Merck, Bayer and Shionogi the CRC market will create a significant positive shift in the market size.
Analyst Comments
- Among all the potential emerging therapies, Gefapixant (MK-7264), which is being developed by Merck is estimated to enter the CRC market at the earliest, as the drug has already completed several phase II and III developmental trials successfully. The drug has demonstrated quite impressive efficacy and consistent safety and tolerability profile. Besides, a major drawback that comes with this therapy is the incidence of serious adverse events and high incidence of taste-related adverse events, which led to few treatment discontinuations. However, due to high unmet needs and lack of approved therapies, the probability of success of Gefapixant is expected to be quite high.
- Another major potential emerging therapy is Orvepitant Maleate (Nerre Therapeutics). This therapy has demonstrated no safety concerns in the treated population with excellent tolerability. Additionally, the reduction in cough frequency in patients was observed to be near significant. Therefore, if approved, this therapy may capture an impressive market share in the forecast period with high compliance rate in comparison to other emerging therapies.
- Furthermore, it is important to note that all the emerging therapies except for Orvepitant Maleate works as an antagonist to P2X3 receptor, however, Nerre Therapeutics’ candidate targets Neurokinin-1 receptor (NK-1RA). As result, all the emerging therapies except for Orvepitant Maleate are expected to face major competition upon approval.
Companies Mentioned:
- Merck
- Nerre Therapeutics
- Bellus Health
- Shionogi
- Bayer
Key Topics Covered:
1 Key Insights
2 Executive Summary
3 Chronic Refractory Cough Market Overview at a Glance
4 Disease Background and Overview: Chronic Refractory Cough (CRC)
5 Epidemiology and Patient Population
6 Country-Wise Epidemiology of Chronic Refractory Cough
7 Recognized Establishment
8 Treatment
9 European Guidelines on Chronic Cough
10 United States Guideline on Chronic Refractory Cough
11 Unmet Needs
12 Emerging Drugs
13 Market Access and Reimbursement
14 Chronic Refractory Cough: Seven Major Market Analysis
15 EU-5 Countries Market Size
16 Japan Market Size
17 Case Report
18 Market Drivers
19 Market Barriers
20 SWOT Analysis
21 KOL Views
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c75jdp
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
